S-1: Cyclacel Pharmaceuticals Announces Best Efforts Public Offering of Common Stock and Warrants

Cyclacel Pharmaceuticals is launching a best efforts public offering of common stock, common stock warrants, and pre-funded warrants to raise capital for working capital and general corporate purposes.

Summary

• Cyclacel Pharmaceuticals has filed a Form S-1 registration statement for a proposed best efforts public offering.
• The offering includes shares of common stock, common stock warrants to purchase common stock, and pre-funded warrants to purchase common stock.
• The company is offering common stock warrants to purchase up to shares of common stock, exercisable immediately upon issuance and expiring five years from the initial exercise date at an exercise price of $ per share.
• Pre-funded warrants are offered to purchasers whose acquisition of common stock would exceed beneficial ownership limits of 4.99% or 9.99%, with each pre-funded warrant exercisable for one share of common stock at $0.0001 per share.
• The offering price will be determined between the company, the placement agent, and investors, and may be at a discount to the current market price.
• The company intends to use the net proceeds from this offering for working capital and general corporate purposes.
• Roth Capital Partners, LLC is acting as the exclusive placement agent for the offering.
• The offering will terminate on the earlier of the date the company enters into securities purchase agreements or a specified date in 2024.
• The company's common stock is quoted on the Nasdaq Capital Market under the symbol CYCC; however, the company does not intend to apply for listing of the Common Stock Warrants or pre-funded warrants on any national securities exchange or trading system.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The announcement is a standard capital raise, which is neither overwhelmingly positive nor negative. The company needs funds, but the terms of the offering include warrants, which can be dilutive.

Positives

• The company retains rights to commercialize its clinical development candidates and aims to enter into selective partnership arrangements.
• The company believes that fadraciclib's inhibition of CDK2 and CDK9 may be superior to inhibiting either CDK2 or CDK9 alone.

Negatives

• The actual public offering price per share and accompanying Common Stock Warrant will be determined between the company, Placement Agent and the investors in the offering, and may be at a discount to then current market price of the company's common stock.
• There is no established public trading market for the Common Stock Warrants or pre-funded warrants, and the company does not expect such markets to develop.
• Without an active trading market, the liquidity of the Common Stock Warrants and the pre-funded warrants will be limited.
• The Placement Agent has no obligation to purchase any of the securities from the company or to arrange for the purchase or sale of any specific number or dollar amount of the securities.
• Because there is no minimum offering amount required as a condition to closing in this offering the actual public amount, placement agents fee, and proceeds to us, if any, are not presently determinable and may be substantially less than the total maximum offering amounts set forth above and throughout this prospectus.

Risks

• Investing in the company's securities involves a high degree of risk, as detailed in the Risk Factors section of the prospectus.
• The company has broad discretion in the use of the net proceeds from this offering and may not use them effectively.
• Investors will experience immediate and substantial dilution in the net tangible book value of the shares they purchase in this offering and may experience additional dilution in the future.
• There is no public market for the Common Stock Warrants or pre-funded warrants being offered by the company in this offering.
• The Common Stock Warrants and pre-funded warrants are speculative in nature.
• This is a best efforts offering, no minimum amount of securities is required to be sold, and the company may not raise the amount of capital it believes is required for its business plans, including its near-term business plans.

Future Outlook

The company estimates that the net proceeds of this offering, together with its existing cash and cash equivalents, will be sufficient to fund its operating expenses and capital expenditure requirements through at least .

Industry Context

Many clinical-stage biopharmaceutical companies rely on public offerings to fund ongoing research and development activities, especially those focused on oncology and hematology indications.

Comparison to Industry Standards

• The terms of the offering, including the use of best efforts and the inclusion of warrants, are common in financings for smaller reporting companies in the biotechnology sector.
• Comparable companies that have recently conducted similar offerings include [Competitor A] and [Competitor B], although the specific terms may vary based on market conditions and company-specific factors.

Management Changes

Related Party Transactions

• On December 21, 2023, in an insider private placement, the company sold shares of common stock and warrants to purchase shares of common stock to Spiro Rombotis, the Chief Executive Officer, and Paul McBarron, the Executive Vice President-Finance, Chief Financial Officer and Chief Operating Officer.

Stakeholder Impact

• Shareholders may experience dilution as a result of the offering.
• The company's ability to fund its operations and clinical trials may be enhanced by the proceeds of the offering.

Next Steps

• The company will determine the final offering price and terms in consultation with the placement agent and investors.
• The company will seek to complete the offering and receive the net proceeds for its intended use.

Key Dates

Keywords

public offering, common stock, warrants, pre-funded warrants, Roth Capital Partners, capital raise, biopharmaceutical, oncology, hematology, clinical trials, fadraciclib, plogosertib, CYCC